George Nakayama, Chairman and CEO Antoine Yver MD MSc Exec VP & Global Head R&D Oncology PLAY LIST from the beginning FY2018 R&D Day Forward-Looking Statements Toward 2025 Vision & 5-Year Business Plan Establish Oncology Business Continuously Generate Innovative Medicine Changing SOC R&D 2025 Vision R&D 2025 Vision Daiichi Sankyo Cancer Enterprise: Deliver, Scale Up and Lead in Science Today's Agenda 1 Cancer Enterprise 2025 Daiichi Sankyo Cancer Enterprise 2025 Cancer Enterprise 2025: Multiple Opportunities for 7 new drugs CE is a Virtual Organization that Delivers ADC Manufacturing: Meeting Massive Increase in Demand CE is Scaling Up the Enterprise Daiichi Sankyo | A Traditional Japanese Company Transforming into a Global Power CE Leadership in Science Enhanced ADC Technology Daiichi Sankyo ADC Franchise 2 DS-8201 ADC | DS-8201 (fam-trastuzumab deruxtecan) Top News Clinical Program Clinical Program Drug-related ILD (Interstitial lung disease) Safety: ILD Safety: ILD ILD experience Breast Cancer at Recommended Dose HER2 Positive Breast Cancer: New Data HER2 Low Breast Cancer HER2 Low Breast Cancer P3 Study Design HER2 Positive Gastric Cancer NSCLC HER2 Mutated or Expressing CRC by HER2 Status IHC/FISH Patient Selection & CDx Strategy DS-8201 is Leading the Second Generation HER2 ADC Race with the Most Ongoing Trials What Have We Learned? 3 U3-1402 U3-1402 (HER3 ADC): First Time in Human Safety Profile to Date (Nov. 06, 2018) Efficacy Data in Ph 1, Breast Cancer Study Efficacy by Dose Level in Ph 1 BC Study NSCLC Ph 1 Study HER3 Expression in Cancer (IHC) Directional Development Plan HER2 and HER3 ADCs' Overlap 4 Next DXd ADCs DS-1062 TROP2 ADC | Ph 1 Study : Lean Plan to POC B7-H3 | An Attractive Target for ADC Therapy DS-6157 | First-in Class GPR20 ADC 5 Quizartinib AML/Hematology | Steady Progress Refractory / Relapsed FLT3-ITD AML Highly Potent and Selective Type II Kinase Inhibitor Clarification of the Mechanism of Action QuANTUM-FIRST | Front-line AML 6 Pexidartinib TGCT is Rare, Non-malignant Disease with Large Pool of Prevalent Patients Proposed Indication ENLIVEN Study Efficacy & Safety 7 Recap Cancer Enterprise | Major Clinical Pipeline Cancer Enterprise | Upcoming Milestones Cancer Enterprise | Deliver, Scale Up, Lead Contact address regarding this material HER3 ADCs TROP2 ADCs B7-H3 ADCs GPR20 ADCs HER3 Protein Expression Across Cancers TROP2 Expression in Various Cancers B7-H3 Protein Expression in Various Cancers Abbreviations Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Q&A 8 Q&A 9 Back Next